Pitavastatin Calcium
Catalog No.S1759 Synonyms: NK-104, P-872441, itavastatin, nisvastatin
Molecular Weight(MW): 880.98
Pitavastatin calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor.
3 Customer Reviews
-
Western blotting showed that in U87 cells treated with pitavastatin, the LC3-II isoform dramatically increased after statin treatment and showed at day 2, 3 and 4.
Br J Cancer, 2014, 111(8): 1562-71 . Pitavastatin Calcium purchased from Selleck.
Fewer proliferative cells were detected in the tumour after pitavastatin treatment according to the Ki67 staining results but not in fluvastatin group.
Br J Cancer, 2014, 111(8): 1562-71 . Pitavastatin Calcium purchased from Selleck.
-
Western blot analysis of Nrf2, NQO1, and HO-1 in statin-treated VSMCs. Cells were exposed to fluvastatin and pitavastatin for 24 h at the indicated dosages. In addition, protein samples were refined from cultured VSMCs treated with fluvastatin (5 μM) or pitavastatin (5 μM) for the indicated times.
PLoS One, 2017, 12(5):e0178278. Pitavastatin Calcium purchased from Selleck.
Purity & Quality Control
Choose Selective HMG-CoA Reductase Inhibitors
Biological Activity
| Description | Pitavastatin calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Pitavastatin significantly reduces both intracellular levels and synthesis of cholesterol esters. Pitavastatin is found to enhance LDL-receptor expression in vitro, as well as the amount of LDL binding to the LDL-receptor. Pitavastatin also exhibits more potent induction of LDL receptor mRNA expression compared with simvastatin and atorvastatin. Pitavastatin has many pleiotropic effects in vitro and in vivo, including deterring progression of atherosclerosis via inhibition of thromboxane synthesis, inhibition of migration/proliferation of vascular smooth muscle cells induced by angiotensin II, and stabilization of atherosclerotic plaque. [1] Pitavastatin is able to activate PPARα and induce HDL apoA-I through inducing inhibition of the Rho-signaling pathway. [2] Pitavastatin (1 μM) treatment for 48 h is able to enhances bone morphogenetic protein-2 BMP-2 (2.5-fold) and osteocalcin (10-fold) expression by inhibition of Rho-associated kinase in human osteoblasts[3]. Pitavastatin inhibits growth and colony formation of liver cancer Huh-7 cells and SMMC7721 cells. It induces arrest of liver cancer cells at the G1 phase. Increased proportion of sub-G1 cells is observed after pitavastatin treatment. Pitavastatin promotes caspase-9 cleavage and caspase-3 cleavage in liver cancer cells. Pitavastatin could regulate NF-κB and anti-inflammation in hepatocellular carcinoma cells. Pitavastatin could induce autophagic cell death in glioma cells and promote sensitivity of cells to radiotherapy. It could inhibit cell proliferation and induce cell apoptosis in cholangiocarcinoma cells as well[5]. |
||
| In vivo | Pitavastatin decreases the tumor growth and improved the survival of tumor-bearing mice[5]. Pitavastatin exerts a protective effect on dilated cardiomyopathy possibly through down-regulating the circulating and local RAS, followed by inhibition of PKCb2 phosphorylation, and consequently promoting the phosphorylation of PLB as well as the activity and the expressions of SERCA2a and RyR2, whereby heart function is preserved in the development of DCM[6]. |
Protocol
| Cell Research: |
+ Expand
|
|---|---|
| Animal Research: |
+ Expand
|
Solubility (25°C)
| In vitro | DMSO | 51 mg/mL (57.89 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 880.98 |
|---|---|
| Formula | C50H46CaF2N2O8 |
| CAS No. | 147526-32-7 |
| Storage | powder |
| in solvent | |
| Synonyms | NK-104, P-872441, itavastatin, nisvastatin |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03730038 | Not yet recruiting | Dyslipidemias | Yonsei University | March 2019 | Not Applicable |
| NCT03606824 | Recruiting | Dyslipidemia|Subclinical hypothyroïdism|Statin|ASCVD | Shaochun.Li|Chinese Academy of Medical Sciences Fuwai Hospital|Peking University Third Hospital|Beijing Chao Yang Hospital|Xuanwu Hospital Beijing|Beijing Friendship Hospital|China National Center for Cardiovascular Diseases | March 25 2019 | Not Applicable |
| NCT03730038 | Not yet recruiting | Dyslipidemias | Yonsei University | March 2019 | Not Applicable |
| NCT03606824 | Recruiting | Dyslipidemia|Subclinical hypothyroïdism|Statin|ASCVD | Shaochun.Li|Chinese Academy of Medical Sciences Fuwai Hospital|Peking University Third Hospital|Beijing Chao Yang Hospital|Xuanwu Hospital Beijing|Beijing Friendship Hospital|China National Center for Cardiovascular Diseases | March 25 2019 | Not Applicable |
| NCT03717064 | Completed | Healthy Volunteers | Hoffmann-La Roche | November 7 2018 | Phase 1 |
| NCT03717064 | Completed | Healthy Volunteers | Hoffmann-La Roche | November 7 2018 | Phase 1 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
-
Question 1:
How to prepare the solution of the compound (S1759) for in vivo use?
-
Answer:
You could use the formulation: 5% DMSO +40%PEG 300+5%Tween80+ddH2O for i.p., at a working concentration of 12.5mg/ml, stable for no longer than 40min.
